Aziz Mottiwala - 15 Mar 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Commercial Officer
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
15 Mar 2025
Net transactions value
$0
Form type
4
Filing time
18 Mar 2025, 21:38:49 UTC
Previous filing
07 Mar 2025
Next filing
20 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise +20,957 +38% 75,622 15 Mar 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Restricted Stock Units Options Exercise $0 -4,790 -50% $0.000000 4,790 15 Mar 2025 Common Stock 4,790 Direct F3, F4
transaction TARS Restricted Stock Units Options Exercise $0 -8,148 -33% $0.000000 16,296 15 Mar 2025 Common Stock 8,148 Direct F3, F5
transaction TARS Restricted Stock Units Options Exercise $0 -8,019 -25% $0.000000 24,060 15 Mar 2025 Common Stock 8,019 Direct F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
F2 Includes 590 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024 and December 31, 2024.
F3 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F4 RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.
F5 RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
F6 RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.